Remdesivir and COVID-19
- PMID: 33010832
- PMCID: PMC7529398
- DOI: 10.1016/S0140-6736(20)32020-1
Remdesivir and COVID-19
Comment in
-
Remdesivir and COVID-19 - Authors' reply.Lancet. 2020 Oct 3;396(10256):954. doi: 10.1016/S0140-6736(20)32015-8. Lancet. 2020. PMID: 33010835 Free PMC article. No abstract available.
Comment on
-
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Lancet. 2020. PMID: 32423584 Free PMC article. Clinical Trial.
Similar articles
-
Remdesivir and COVID-19.Lancet. 2020 Oct 3;396(10256):952. doi: 10.1016/S0140-6736(20)32021-3. Lancet. 2020. PMID: 33010831 Free PMC article. No abstract available.
-
Remdesivir and COVID-19.Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5. Lancet. 2020. PMID: 33010833 Free PMC article. No abstract available.
-
Remdesivir and COVID-19: What are the implications for Africa?S Afr Med J. 2020 May 7;110(6):12942. S Afr Med J. 2020. PMID: 32880546 No abstract available.
-
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217. J R Coll Physicians Edinb. 2020. PMID: 32568289 Review. No abstract available.
-
A Review of Remdesivir for COVID-19: Data to Date.Cardiol Rev. 2020 Nov/Dec;28(6):332-334. doi: 10.1097/CRD.0000000000000337. Cardiol Rev. 2020. PMID: 32773440 Review.
Cited by
-
High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses.Viruses. 2022 Jun 24;14(7):1381. doi: 10.3390/v14071381. Viruses. 2022. PMID: 35891362 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources